Synthesis, radiofluorination and first evaluation of (±)-[ 18F]MDL 100907 as serotonin 5-HT2A receptor antagonist for PET

Journal of Labelled Compounds and Radiopharmaceuticals

Volumn 52, Issue 1, 2009, Pages 6-12

  Mühlhausen, Ute ^a   Ermert, Johannes ^a   Herth, Matthias M ^b   Coenen, Heinz H ^a  

^a FORSCHUNGSZENTRUM JÜLICH   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

( ) 18F MDL 100907; 1 (2 bromoethyl) 4 18F fluorobenzene; 5 HT2A antagonist; PET; Radiofluorination

Indexed keywords

RADIOGRAPHY;

(±)-[18F]MDL 100907; 1-(2-BROMOETHYL)-4-[18F]FLUOROBENZENE; 5-HT2A ANTAGONIST; FLUOROBENZENE; HIGH AFFINITY; IN-VIVO; PSYCHIATRIC DISORDERS; RADIOFLUORINATION; RADIOLIGANDS; RECEPTOR ANTAGONISTS;

POSITRON EMISSION TOMOGRAPHY;

FLUORINE 18; KETANSERIN; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SPIPERONE; UNCLASSIFIED DRUG; VOLINANSERIN; VOLINANSERIN F 18;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; FLUORINATION; FRONTAL CORTEX; ISOTOPE LABELING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOCHEMISTRY; RAT;

RATTUS;

EID: 58149469082     PISSN: 03624803     EISSN: 10991344     Source Type: Journal    
DOI: 10.1002/jlcr.1563     Document Type: Article

References (23)

1. M. Naughton, J. B. Mulrooney, B. E. Leonard, Hum. Psychopharmaco. 2000, 15, 397-415.
2. E. K. Perry, R. H. Perry, J. M. Candy, A. F. Fairbairn, G. Blessed, D. J. Dick, B. E. Tomlinson, Neurosci. Lett. 1984, 51, 353-357.
3. B. Dean, W. Hayes. Schizophr. Res. 1996, 21, 133-139.
4. C. Lundkvist, C. Halldin, N. Ginovart, S. Nyberg, C.-G. Swahn, A. A. Carr, F. Brunner, L. Farde, Life Sci. 1996, 58, 187-192.
5. M. P. Johnson, B. W. Siegel, A. A. Carr, Naunyn-Schmiedeberg's Arch. Pharmacol. 1996, 354, 205-209.
6. J. E. Leysen, in Neuromethods: Drugs as Tools in Neurotransmitter Research (Eds.: A. A. Boulton, G. B. Baker, A. V. Juorio), Humana Press, Clifton, NJ, 1989, pp. 299-350.
7. H. Kristiansen, B. Elfving, P. Plenge, L. H. Pinborg, N. Gillings, G. M. Knudsen, Synapse 2005, 58, 249-257.
8. P. Z. Tan, R. M. Baldwin, C. H. Van Dyck, M. Al-Tikriti, B. Roth, N. Khan, D. S Charney, R. B. Innis, Nucl. Med. Biol. 1999, 26, 601-608.
9. H. Hall, L. Farde, C. Halldin, C. Lundkvist, G. Sedvall, Synapse 2000, 38, 421-431.
10. D. O. Scott, T. G. Heath, J. Pharm. Biomed. Anal. 1998, 17, 17-25.
11. H. Ito, S. Nyberg, C. Halldin, C. Lundkvist, L. Farde, J. Nucl. Med. 1998, 39, 208-214.
12. C. A. Mathis, K. Mahmood, Y. Huang, N. R. Simpson, J. M. Gerdes, J. C. Price, Med. Chem. Res. 1996, 6, 1-10.
13. A. A. Carr, J. M. Kane, D. A. Hay, PCT Int. Appl. 1991; WO 91/18602.
14. Y. Huang, K. Mahmood, C. A. Mathis, J. Labelled Cpd. Radiopharm. 1999, 42, 949-957.
15. T. Ullrich, K. C. Rice, Bioorg. Med. Chem. 2000, 8, 2427-2432.
16. D.-R. Hwang, C. S. Dence, J. Gong, M. J. Welch, Appl. Radiat. Isot. 1991, 42, 1043-1047.
17. C. S. Dence, T. J. McCarthy, M. J. Welch, Appl. Radiat. Isot. 1993, 44, 981-983.
18. E. F. J. de Vries, J. Vroegh, P. H. Elsinga, W. Vaalburg, Appl. Radiat. Isot. 2003, 58, 469-476.
19. W. R. Banks, D. R. Hwang, Appl. Radiat. Isot. 1994, 45, 599-608.
20. J. F. López-Giménez, G. Mengod, J. M. Palacios, M. T. Vilaró, Naunyn-Schmiedeberg's Arch. Pharmacol. 1997, 356, 446-454.
21. A. Pazos, R. Cortés, J. M. Palacios, Brain Res. 1985, 346, 231-249.
22. S. M. Qaim, J. C. Clark, C. Crouzel, M. Guillaume, H. J. Helmecke, B. Nebeling, V. W. Pike, G. Stöcklin, PET radionuclide production, in Radiopharmaceuticals for PET (Eds.: G. Stöcklin, V. W. Pike), Kluwer Academic Publishers, Dordrecht, 1993, pp. 15-26.
23. H. H. Coenen, B. Klatte, A. Knöchel, M. Schüller, G. J. Stöcklin, J. Label. Compd. Radiopharm. 1986, 23, 455-466.